Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 114 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Menopause Hot Flashes Clear all

Conditions: Hot Flashes, Menopause, Vasomotor Symptoms
Interventions: Placebo, Omega-3, Yoga, Exercise, Usual Activity; Dietary Supplement · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Oakland, California • Indianapolis, Indiana • Seattle, Washington

Conditions: Menopause
Interventions: Estradiol, Progesterone, Placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,845 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 119
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more

Conditions: Breast Cancer, Hot Flashes, Menopausal Symptoms
Interventions: conjugated estrogens, medroxyprogesterone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 24
States / cities: Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Menopause, Hot Flashes
Interventions: iButton®; Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Postmenopausal Symptoms
Interventions: G-CSF, Placebo/Saline; Biological · Other
Lead sponsor: MenoGeniX, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Menopause-related Hot Flashes
Interventions: Yoga; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hot Flashes, Menopause, Vasomotor Disturbance, Sleep
Interventions: Cognitive Behavioral Therapy-Insomnia (CBT-I), Menopause Education Control (MEC); Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Menopause, Hot Flashes
Interventions: Hormone Replacement Therapy, Cimicifuga racemosa (Black Cohosh), Multibotanical phytoestrogen formula; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes, Hot Flash, Night Sweats, Vasomotor Symptoms
Interventions: JDS-HF3.0, Placebo; Dietary Supplement · Other
Lead sponsor: Bonafide Health; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Sugar pill; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 41 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Lake Worth, Florida • Naples, Florida • Greensboro, North Carolina + 6 more

Conditions: Hot Flashes, Night Sweats
Interventions: Estradiol; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Postmenopausal Symptoms
Interventions: Brisdelle (paroxetine mesylate); Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vasomotor Symptoms, Menopause
Interventions: FP-101; Drug
Lead sponsor: Fervent Pharmaceuticals; Industry
Eligibility: 46 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Lomita, California • Long Beach, California • West Covina, California + 8 more

Conditions: Hot Flashes, Menopause, Vasomotor Symptoms
Interventions: Escitalopram, Placebo; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more

Conditions: Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions: JDS-HF3.0; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Menopausal Symptoms
Interventions: Isoflavone supplement; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 38 Years to 65 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause
Interventions: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg); Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 35 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Hot Flashes
Interventions: Gabapentin, Estrogen and placebo administration; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Post-menopausal Vasomotor Symptoms
Interventions: BAY3427080, Placebo (for BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: DeLand, Florida • Miami, Florida • San Antonio, Texas

Conditions: Treatment of Menopausal Hot Flashes
Interventions: Standard Dose Kappa Agonist, Half Dose Kappa Agonist, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hot Flashes
Interventions: fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 142
States / cities: Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more

Conditions: Vasomotor Symptoms
Interventions: desvenlafaxine succinate (DVS) SR, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 2,186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more

Conditions: Menopause, Hot Flashes
Interventions: PhytoSERM, Placebo; Dietary Supplement · Drug
Lead sponsor: NeuTherapeutics; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Menopause
Interventions: Armodafinil; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Validation of an Objective Instrument to Measure Hot Flashes During Menopause

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

Yoga for Treatment of Hot Flashes

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance

Alternative Therapies for Menopause: A Randomized Trial

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

Effects of Soy Isoflavones on Menopausal Hot Flashes

Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

Gabapentin Versus Estrogen for the Treatment of Hot Flashes

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health

Effect of Nuvigil on Fatigue